9 Literaturverzeichnis

1. Braunwald,E. *et al.* ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). *Circulation* 102, 1193-1209 (2000).

2. Statistisches Bundesamt,W.2. Ergebnisse der Todesursachenstatistik für Deutschland - ausführliche vierstellige ICD10-Klassifikation 2004. 08. Dezember 2005(5232101047005). 2006. Ref Type: Generic

3. Tunstall-Pedoe,H. *et al.* Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation* 90, 583-612 (1994).

4. Libby,P. Inflammation in atherosclerosis. *Nature* 420, 868-874 (2002).

5. Libby,P., Ridker,P.M. & Maseri,A. Inflammation and atherosclerosis. *Circulation* 105, 1135-1143 (2002).

6. Lusis,A.J. Atherosclerosis. *Nature* 407, 233-241 (2000).

7. Libby,P. Current concepts of the pathogenesis of the acute coronary syndromes. *Circulation* 104, 365-372 (2001).

8. Fox,K.A. Management of acute coronary syndromes: an update. *Heart* 90, 698-706 (2004).

9. Fuster,V. *et al.* Atherosclerotic plaque rupture and thrombosis. Evolving concepts. *Circulation* 82, II47-II59 (1990).

10. Libby,P. Vascular biology of atherosclerosis: overview and state of the art. *Am. J. Cardiol.* 91, 3A-6A (2003).

11. Riess,H. [Hemostasis--an finely regulated protective mechanism? Pathophysiology of venous thromboembolism]. *Pharm. Unserer Zeit* 33, 166-171 (2004).

12. Tariverdian & Buselmaier. Humangenetik., pp. 3-22 (Springer Verlag, Berlin, Heidelberg, New York,2004).

13. Doris,P.A. Hypertension genetics, single nucleotide polymorphisms, and the common disease:common variant hypothesis. *Hypertension* 39, 323-331 (2002).

14. Cargill,M. *et al.* Characterization of single-nucleotide polymorphisms in coding regions of human genes. *Nat. Genet.* 22, 231-238 (1999).

15. Knippers R. Molekulare Genetik. Knippers R (ed.), pp. 227-259 (Georg Thieme Verlag, Stuttgart, New York,1995).

16. Cambien,F. *et al.* Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. *Nature* 359, 641-644 (1992).

17. Kee,F. *et al.* Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study. Etude cas-temoin de l'infarctus myocarde. *Heart* 84, 548-552 (2000).

18. Agarwal,A.K. *et al.* CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity. *Hypertension* 36, 187-194 (2000).

19. De Backer,G. *et al.* A comparison of lifestyle, genetic, bioclinical and biochemical variables of offspring with and without family histories of premature coronary heart disease: the experience of the European Atherosclerosis Research Studies. *J. Cardiovasc. Risk* 6, 183-188 (1999).

20. Wilhelmsen,L. *et al.* Fibrinogen as a risk factor for stroke and myocardial infarction. *N. Engl. J. Med.* 311, 501-505 (1984).

21. Marenberg,M.E., Risch,N., Berkman,L.F., Floderus,B. & de Faire,U. Genetic susceptibility to death from coronary heart disease in a study of twins. *N. Engl. J. Med.* 330, 1041-1046 (1994).

22. O'Donnell,C.J. *et al.* Genetic and environmental contributions to platelet aggregation: the Framingham heart study. *Circulation* 103, 3051-3056 (2001).

23. Hayden,M.R. *et al.* DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. *Am. J. Hum. Genet.* 40, 421-430 (1987).

24. Tiret,L. *et al.* Heterogeneity of linkage disequilibrium in human genes has implications for association studies of common diseases. *Hum. Mol. Genet.* 11, 419-429 (2002).

25. Herrmann,S.M. & Paul,M. Studying genotype-phenotype relationships: cardiovascular disease as an example. *J. Mol. Med.* 80, 282-289 (2002).

26. Smith,F.B. *et al.* Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. *Eur. Heart J.* 21, 1607-1613 (2000).

27. Mosesson,M.W. Fibrinogen gamma chain functions. *J. Thromb. Haemost.* 1, 231-238 (2003).

28. Yu,S., Sher,B., Kudryk,B. & Redman,C.M. Fibrinogen precursors. Order of assembly of fibrinogen chains. *J. Biol. Chem.* 259, 10574-10581 (1984).

29. Hawiger,J., Timmons,S., Kloczewiak,M., Strong,D.D. & Doolittle,R.F. gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. *Proc. Natl. Acad. Sci. U. S. A* 79, 2068-2071 (1982).

30. Jaeger,B.R. & Labarrere,C.A. [Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?]. *Herz* 28, 530-538 (2003).

31. Meade,T.W. *et al.* Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. *Lancet* 2, 533-537 (1986).

32. Acevedo,M., Pearce,G.L., Kottke-Marchant,K. & Sprecher,D.L. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. *Arterioscler. Thromb. Vasc. Biol.* 22, 1042-1045 (2002).

33. Acevedo,M., Foody,J.M., Pearce,G.L. & Sprecher,D.L. Fibrinogen: associations with cardiovascular events in an outpatient clinic. *Am. Heart J.* 143, 277-282 (2002).

34. Hamsten,A., Iselius,L., de Faire,U. & Blomback,M. Genetic and cultural inheritance of plasma fibrinogen concentration. *Lancet* 2, 988-991 (1987).

35. Humphries,S.E. Genetic regulation of fibrinogen. *Eur. Heart J.* 16 Suppl A, 16-19 (1995).

36. Humphries,S.E., Cook,M., Dubowitz,M., Stirling,Y. & Meade,T.W. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. *Lancet* 1, 1452-1455 (1987).

37. Farrell,D.H., Thiagarajan,P., Chung,D.W. & Davie,E.W. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. *Proc. Natl. Acad. Sci. U. S. A* 89, 10729-10732 (1992).

38. Fuller,G.M. & Zhang,Z. Transcriptional control mechanism of fibrinogen gene expression. *Ann. N. Y. Acad. Sci.* 936:469-79., 469-479 (2001).

39. Alving,B.M. & Henschen,A.H. Fibrinogen giessen I: a congenital homozygously expressed dysfibrinogenemia with A alpha 16 Arg----His substitution. *Am. J. Hematol.* 25, 479-482 (1987).

40. Beck,E.A., Charache,P. & Jackson,D.P. A new inherited coagulation disorder caused by an abnormal fibrinogen ('fibrinogen Baltimore'). *Nature* 208, 143-145 (1965).

41. Yoshida,N. *et al.* Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized by the replacement of A alpha proline-18 by leucine. *Blood* 78, 149-153 (1991).

42. Manzoli,A. *et al.* Vascular and haemostatic gene polymorphisms associated with non-fatal myocardial infarction: a critical review. *Ital. Heart J.* 1, 184-193 (2000).

43. Behague,I. *et al.* Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. *Circulation* 93, 440-449 (1996).

44. Weiss,E.J. *et al.* A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. *N. Engl. J. Med.* 334, 1090-1094 (1996).

45. Powers,J. *et al.* Proteases, Proteases-Inhibitors and Proteases derived peptides. Cheronis J.C. & Repine J.E. (eds.), pp. 3-18 (Birkhäuser, Basel, Boston Berlin,1993).

46. Stockley,R.A. Neutrophils and protease/antiprotease imbalance. *Am. J. Respir. Crit Care Med.* 160, S49-S52 (1999).

47. Stockley,R.A. Proteases and antiproteases. *Novartis. Found. Symp.* 234, 189-199 (2001).

48. Berg,J.M., Tymoczko,J.L. & Stryer,L. Biochemie. 5. Aufl. 2003, 252-256. 2006. Ref Type: Generic

49. Sinha,S. *et al.* Primary structure of human neutrophil elastase. *Proc. Natl. Acad. Sci. U. S. A* 84, 2228-2232 (1987).

50. Nakamura,H., Okano,K., Aoki,Y., Shimizu,H. & Naruto,M. Nucleotide sequence of human bone marrow serine protease (medullasin) gene. *Nucleic Acids Res.* 15, 9601-9602 (1987).

51. Zimmer,M. *et al.* Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. *Proc. Natl. Acad. Sci. U. S. A* 89, 8215-8219 (1992).

52. Yoshimura,K., Chu,C.S. & Crystal,R.G. Enhancer function of a 53-bp repetitive element in the 5' flanking region of the human neutrophil elastase gene. *Biochem. Biophys. Res. Commun.* 204, 38-42 (1994).

53. Aoki,Y. Crystallization and characterization of a new protease in mitochondria of bone marrow cells. *J. Biol. Chem.* 253, 2026-2032 (1978).

54. Doring,G. The role of neutrophil elastase in chronic inflammation. *Am. J. Respir. Crit Care Med.* 150, S114-S117 (1994).

55. Dinerman,J.L. *et al.* Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. *J. Am. Coll. Cardiol.* 15, 1559-1563 (1990).

56. Tiefenbacher,C.P. *et al.* Inhibition of elastase improves myocardial function after repetitive ischaemia and myocardial infarction in the rat heart. *Pflugers Arch.* 433, 563-570 (1997).

57. Kornecki,E., Ehrlich,Y.H., De Mars,D.D. & Lenox,R.H. Exposure of fibrinogen receptors in human platelets by surface proteolysis with elastase. *J. Clin. Invest* 77, 750-756 (1986).

58. Kornecki,E. *et al.* Granulocyte-platelet interactions and platelet fibrinogen receptor exposure. *Am. J. Physiol* 255, H651-H658 (1988).

59. Si-Tahar,M. *et al.* Human neutrophil elastase proteolytically activates the platelet integrin alphaIIbbeta3 through cleavage of the carboxyl terminus of the alphaIIb subunit heavy chain. Involvement in the potentiation of platelet aggregation. *J. Biol. Chem.* 272, 11636-11647 (1997).

60. Mathur,A., Zhong,D., Sabharwal,A.K., Smith,K.J. & Bajaj,S.P. Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X. *J. Biol. Chem.* 272, 23418-23426 (1997).

61. Horwitz,M., Benson,K.F., Person,R.E., Aprikyan,A.G. & Dale,D.C. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. *Nat. Genet.* 23, 433-436 (1999).

62. Visvikis,S. *et al.* Apolipoprotein B signal peptide polymorphism in patients with myocardial infarction and controls. "The ECTIM study". *Hum. Genet.* 90, 561-565 (1993).

63. Parra,H.J. *et al.* A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. *Arterioscler. Thromb.* 12, 701-707 (1992).

64. Miller,S.A., Dykes,D.D. & Polesky,H.F. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res.* 16, 1215 (1988).

65. Orita,M., Iwahana,H., Kanazawa,H., Hayashi,K. & Sekiya,T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. *Proc. Natl. Acad. Sci. U. S. A* 86, 2766-2770 (1989).

66. Budowle,B., Chakraborty,R., Giusti,A.M., Eisenberg,A.J. & Allen,R.C. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. *Am. J. Hum. Genet.* 48, 137-144 (1991).

67. Ota,T. & Nei,M. Variance and covariances of the numbers of synonymous and nonsynonymous substitutions per site. *Mol. Biol. Evol.* 11, 613-619 (1994).

68. Nei,M. Relative roles of mutation and selection in the maintenance of genetic variability. *Philos. Trans. R. Soc. Lond B Biol. Sci.* 319, 615-629 (1988).

69. Yoshimura,K. & Crystal,R.G. Transcriptional and posttranscriptional modulation of human neutrophil elastase gene expression. *Blood* 79, 2733-2740 (1992).

70. Li,F.Q. & Horwitz,M. Characterization of mutant neutrophil elastase in severe congenital neutropenia. *J. Biol. Chem.* 276, 14230-14241 (2001).

71. Hayashi,K. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. *PCR Methods Appl.* 1, 34-38 (1991).

72. Hayashi,K. & Yandell,D.W. How sensitive is PCR-SSCP? *Hum. Mutat.* 2, 338-346 (1993).

73. Eng,C. *et al.* Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. *J. Med. Genet.* 38, 824-833 (2001).

74. Gross,E., Arnold,N., Goette,J., Schwarz-Boeger,U. & Kiechle,M. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. *Hum. Genet.* 105, 72-78 (1999).

75. Choy,Y.S. *et al.* Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2. *Ann. Hum. Genet.* 63 (Pt 5), 383-391 (1999).

76. Cambien,F. *et al.* Sequence diversity in 36 candidate genes for cardiovascular disorders. *Am. J. Hum. Genet.* 65, 183-191 (1999).

77. Humphries,S.E. *et al.* Genetic factors determining thrombosis and fibrinolysis. *Ann. Epidemiol.* 2, 371-385 (1992).

78. Menegatti,M. *et al.* Identification of four novel polymorphisms in the Aalpha and gamma fibrinogen genes and analysis of association with plasma levels of the protein. *Thromb. Res.* 103, 299-307 (2001).

79. Grant,P.J. Polymorphisms of coagulation/fibrinolysis genes: gene environment interactions and vascular risk. *Prostaglandins Leukot. Essent. Fatty Acids* 57, 473-477 (1997).

80. Grove,E.L., Orntoft,T.F., Lassen,J.F., Jensen,H.K. & Kristensen,S.D. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. *J. Intern. Med.* 255, 637-644 (2004).

81. Kenny,D., Muckian,C., Fitzgerald,D.J., Cannon,C.P. & Shields,D.C. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. *J. Thromb. Thrombolysis.* 13, 13-19 (2002).

82. Resch,K.L. & Ernst,E. Fibrinogen and viscosity: risk factors for cardiovascular events. *Compr. Ther.* 20, 170-173 (1994).

83. Ernst,E. & Resch,K.L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann. Intern. Med.* 118, 956-963 (1993).

84. Danesh,J., Collins,R., Appleby,P. & Peto,R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA* 279, 1477-1482 (1998).

85. Curran,J.M. *et al.* The alpha fibrinogen T/A312 polymorphism in the ECTIM study. *Thromb. Haemost.* 79, 1057-1058 (1998).

86. Fellowes,A.P., Brennan,S.O. & George,P.M. Identification and characterization of five new fibrinogen gene polymorphisms. *Ann. N. Y. Acad. Sci.* 936, 536-541 (2001).

87. Scarabin,P.Y. *et al.* Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. *Arterioscler. Thromb.* 13, 886-891 (1993).

88. Thomas,A.E., Green,F.R., Lamlum,H. & Humphries,S.E. The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers. *J. Med. Genet.* 32, 585-589 (1995).

89. Thomas,A.E., Green,F.R. & Humphries,S.E. Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels; interaction between allele frequency of the G/A-455 polymorphism, age and smoking. *Clin. Genet.* 50, 184-190 (1996).

90. Montgomery,H.E. *et al.* Human gene for physical performance. *Nature* 393, 221-222 (1998).

91. Montgomery,H.E. *et al.* The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. *Arterioscler. Thromb. Vasc. Biol.* 16, 386-391 (1996).

92. de Maat,M.P. *et al.* Gender-related association between beta-fibrinogen genotype and plasma fibrinogen levels and linkage disequilibrium at the fibrinogen locus in Greenland Inuit. *Arterioscler. Thromb. Vasc. Biol.* 15, 856-860 (1995).

93. Humphries,S.E. *et al.* The identification of a DNA polymorphism of the alpha fibrinogen gene, and the regional assignment of the human fibrinogen genes to 4q26-qter. *Hum. Genet.* 68, 148-153 (1984).

94. Doggen,C.J., Bertina,R.M., Cats,V.M. & Rosendaal,F.R. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. *Br. J. Haematol.* 110, 935-938 (2000).

95. Dale,D.C. *et al.* Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. *Blood* 96, 2317-2322 (2000).

96. Aprikyan,A.A., Liles,W.C., Boxer,L.A. & Dale,D.C. Mutant elastase in pathogenesis of cyclic and severe congenital neutropenia. *J. Pediatr. Hematol. Oncol.* 24, 784-786 (2002).

97. Amaro,A. *et al.* Plasma leukocyte elastase concentration in angiographically diagnosed coronary artery disease. *Eur. Heart J.* 16, 615-622 (1995).

98. Aikawa,M. & Libby,P. Atherosclerotic plaque inflammation: the final frontier? *Can. J. Cardiol.* 20, 631-634 (2004).

99. Kim,W.M. & Kang,K. Enzymatic and molecular biochemical characterizations of human neutrophil elastases and a cathepsin G-like enzyme. *Mol. Cells* 10, 498-504 (2000).

100. Schönfelder,J. *et al.* Neutrophil elastase gene variation and coronary heart disease. in press. 2006.
Ref Type: Generic

101. Fields,P. & Somero,G. Amino acid sequence differences cannot fully explain interspecific variation in thermal sensitivities of gobiid fish A4-lactate dehydrogenases (A4-LDHs). *J. Exp. Biol.* 200, 1839-1850 (1997).

102. Juhan-Vague,I. *et al.* Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. *Arterioscler. Thromb. Vasc. Biol.* 22, 867-873 (2002).

103. Wolfe,C.D. *et al.* Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. *Stroke* 31, 2074-2079 (2000).

104. Taniguchi,K. *et al.* Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. *Clin. Cancer Res.* 8, 1115-1120 (2002).

105. Bantia,S., Mane,S.M., Bell,W.R. & Dang,C.V. Fibrinogen Baltimore I: polymerization defect associated with a gamma 292Gly----Val (GGC----GTC) mutation. *Blood* 76, 2279-2283 (1990).

106. Imanaka,T., Shibazaki,M. & Takagi,M. A new way of enhancing the thermostability of proteases. *Nature* 324, 695-697 (1986).

107. Fouret,P. *et al.* Expression of the neutrophil elastase gene during human bone marrow cell differentiation. *J. Exp. Med.* 169, 833-845 (1989).

108. Han,J., Unlap,T. & Rado,T.A. Expression of the human neutrophil elastase gene: positive and negative transcriptional elements in the 5' flanking region. *Biochem. Biophys. Res. Commun.* 181, 1462-1468 (1991).

109. Fuster,V., Fayad,Z.A. & Badimon,J.J. Acute coronary syndromes: biology. *Lancet* 353 Suppl 2, SII5-SII9 (1999).

110. Ross,R. Cellular and molecular studies of atherogenesis. *Atherosclerosis* 131 Suppl, S3-S4 (1997).

111. Hellstern,P. *et al.* [Gene polymorphisms of hemostasis and coronary risk]. *Med. Klin. (Munich)* 96, 217-227 (2001).

112. Wu,K.K. & Willerson,J.T. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy. *Circulation* 103, 2528-2530 (2001).

113. McCarthy,J.J. Advances in pharmacogenomic research and development. *Mol. Biotechnol.* 25, 275-282 (2003).

114. McCarthy,J.J. & Hilfiker,R. The use of single-nucleotide polymorphism maps in pharmacogenomics. *Nat. Biotechnol.* 18, 505-508 (2000).

115. Scheuner,M.T. Genetic evaluation for coronary artery disease. *Genet. Med.* 5, 269-285 (2003).

116. Izawa,H. *et al.* Prediction of genetic risk for hypertension. *Hypertension* 41, 1035-1040 (2003).

117. Wood,D. Established and emerging cardiovascular risk factors. *Am. Heart J.* 141, S49-S57 (2001).

10 Veröffentlichungen

Artikel

J, Schönfelder, R, Telgmann, V, Nicaud, E, Brand, C, Dördelmann, C, Rüßmann, K, Beining, K, Schmidt-Petersen, A, Evans, F, Kee, C, Morrison, D, Arveiler, F, Cambien, M, Paul, S, Brand-Herrmann.
Neutrophil Elastase gene variation and coronary heart disease.
Pharmacogenetics and Genomics, In press

Telgmann R, Harb B, Ozcelik C, Perrot A, **Schonfelder J**, Nonnenmacher A, Brand M, Schmit-Petersen K, Dietz R, Kreutz R, Osterziel KJ, Paul M, Brand-Herrmann SM.
The G-231A polymorphismen in the endothelin-A receptor gene is associated with lower aortic pressure in patients with dilated cardiomyophathy.
American Journal of Hypertension. 2007 Jan;20(1):32-37..

Brenner D, Labreuche J, Touboul PJ, Schmidt-Petersen K, Poirier O, Perret C, **Schonfelder J,** Combadiere C, Lathrop M, Cambien F, Brand-Herrmann SM, Amarenco P; GENIC Investigators.

Cytokine polymorphisms associated with carotid intima-media thickness in stroke patients.

Stroke. 2006 Jul;37(7):1691-1696

Funke-Kaiser H, Reichenberger F, Kopke K, Herrmann SM, **Pfeifer J**, Orzechowski HD, Zidek W, Paul M, Brand E.
Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation.
Hum Mol Genet. 2003 Feb 15;12(4):423-433

Herrmann SM, Nicaud V, Schmidt-Petersen K, **Pfeifer J**, Erdmann J, McDonagh T, Dargie HJ, Paul M, Regitz-Zagrosek V.
Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: the GLAECO and GLAOLD studies.Eur J Heart Fail. 2002 Dec;4(6):707-12.

Herrmann S, Schmidt-Petersen K, **Pfeifer J**, Perrot A, Bit-Avragim N, Eichhorn C, Dietz R, Kreutz R, Paul M, Osterziel KJ.
A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy.
Eur Heart J. 2001 Oct;22(20):1948-1953.